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ABSTRACT
Elite controllers (ECs) are a rare group of HIV seropositive individuals who are able to control viral replication without antiret-
roviral therapy. The mechanisms responsible for this phenotype, however, have not been fully elucidated. In this study, we ex-
amined CD4 T cell resistance to HIV in a cohort of elite controllers and explored transcriptional signatures associated with
cellular resistance. We demonstrate that a subgroup of elite controllers possess CD4 T cells that are specifically resistant to R5-
tropic HIV while remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses. Tran-
scriptome analysis revealed 17 genes that were differentially regulated in resistant elite controllers relative to healthy controls.
Notably, the genes encoding macrophage inflammatory protein 1 (MIP-1), CCL3 and CCL3L1, were found to be upregulated.
TheMIP-1, MIP-1, and RANTES chemokines are natural ligands of CCR5 and are known to interfere with HIV replication.
For three elite controllers, we observed increased production of MIP-1 and/or MIP-1 at the protein level. The supernatant
from resistant EC cells containedMIP-1 andMIP-1 and was sufficient to confer R5-tropic resistance to susceptible CD4 T
cells. Additionally, this effect was reversed by using inhibitory anti-MIP antibodies. These results suggest that the T cells of these
particular elite controllers may be naturally resistant to HIV infection by blocking R5-tropic viral entry.
IMPORTANCE
HIV is a pandemic health problem, and the majority of seropositive individuals will eventually progress to AIDS unless antiret-
roviral therapy (ART) is administered. However, rare patients, termed elite controllers, have a natural ability to control HIV in-
fection in the absence of ART, but the mechanisms by which they achieve this phenotype have not been fully explored. This pa-
per identifies one mechanism that may contribute to this natural resistance: some elite controllers have CD4 T cells that
produce high levels of MIP chemokines, which block R5-tropic HIV entry. This mechanism could potentially be exploited to
achieve a therapeutic effect in other HIV-seropositive individuals.
In the absence of antiretroviral therapy (ART), the majority ofHIV-seropositive patients have detectable viral loads (VLs) and
experience a slow but inevitable decline in the number of CD4 T
cells, eventually culminating in the development of AIDS. How-
ever, in rare individuals (1% of the HIV-seropositive popula-
tion), viral replication is suppressed to extremely low or undetect-
able levels. These patients, termed elite controllers (ECs), typically
retain relatively high CD4 T cell counts and do not progress to
AIDS, even in the absence of ART (1–4). Sequencing of HIV and in
vitro functional assays suggest that most ECs possess replication-
competent virus (5). Long-term nonprogressors (LTNPs), repre-
senting 2 to 15% of HIV-seropositive patients, are a second
group of individuals with a protective phenotype, in whom the
virus continues to replicate but at a reduced level. In LTNPs, the
CD4 T cell count decline and progression to AIDS are signifi-
cantly delayed (6–9). Genome-wide association studies have re-
vealed several alleles within the human leukocyte antigen B/C
(HLA-B/C) block that are enriched in both HIV ECs and LTNPs
versus individuals with normal HIV disease progression (termed
progressors) (10). Notably, B*57:01, B*27:05, B14/Cw*08:02,
B*52, and A*25 alleles are protective, whereas B*35 and Cw*07
alleles confer an elevated risk. However, some ECs lack protective
HLA alleles, and other HIV-seropositive patients exhibit viremia
and disease progression despite possessing these protective alleles.
Collectively, these alleles account for only 20% of the overall vari-
ance in HIV control (10). Hence, additional mechanisms must
contribute to the virologic suppression characteristic of ECs. De-
termining how ECs are able to control HIV replication may ex-
pand our knowledge of HIV pathogenesis, reveal novel therapeu-
tic targets, and inform vaccine and eradication efforts.
While the mechanisms of viral containment remain largely un-
known, a number of key features have been associated with elite
control (1, 11, 12). ECs exhibit T cell responses that are qualita-
tively different from HIV progressors. CD4 T cells from ECs
retain their ability to proliferate and produce interleukin-2 (IL-2)
in response to HIV (2, 13–15). ECs do not exhibit some of the
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immune changes that are observed in progressors, such as upregu-
lation of cytotoxic-T lymphocyte-associated antigen 4 (CTLA-4)
on CD4 T cells (16, 17). Interestingly, some ECs have been
shown to harbor lower levels of integrated HIV DNA but higher
levels of 2-long terminal repeat (2-LTR) circular HIV DNA, sug-
gesting a block at integration post-nuclear entry (18). CD8 T
cells from ECs also exhibit a more polyfunctional response to HIV,
with greater degranulation and release of multiple cytokines, in-
cluding gamma interferon (IFN-), tumor necrosis factor alpha
(TNF-), IL-2, and macrophage inflammatory protein 1 (MIP-
1) (2, 13, 14, 19–22). Moreover, CD8T cells from ECs exhibit a
superior ability to control HIV in cocultured CD4 T cells,
through cytotoxic activity (23). Because of the complex interplay
of HIV with the host immune system, it is likely that some of these
features reflect the primary mechanisms of elite control, whereas
others reflect downstream effects or events.
Previous studies have yielded conflicting results regarding
whether EC CD4 T cells are resistant to HIV. Several studies
demonstrated that phytohemagglutinin (PHA)-activated CD4T
cells from ECs and LTNPs are fully susceptible to infection (24–
28). Two reports demonstrated that CD3-activated CD4 T cells
from ECs were resistant to HIV infection in culture (29, 30), while
a third study using CD3 activation found comparable HIV infec-
tion in CD4 T cells from ECs versus progressors (31). Two stud-
ies found that unstimulated CD4 T cells from ECs and progres-
sors were equally susceptible to HIV infection (32, 33), while a
third study found that unstimulated CD4 T cells from ECs ex-
hibited a block to viral integration (34). These studies used differ-
ent activation protocols and various viral strains. Thus, it is hard
to ascertain if the conflicting and inconsistent results are a conse-
quence of disparate experimental conditions or dissimilar charac-
teristics of the EC cohorts.
The HIV vectors used in laboratory studies can be engineered
to incorporate different HIV envelopes, which vary in their core-
ceptor usage. CCR5 (R5)-tropic envelopes predominate during
the early stage of clinical HIV infection, while CXCR4 (X4)-tropic
HIV envelopes may evolve as patients progress to AIDS. Addition-
ally, many laboratory studies use HIV vectors pseudotyped with
vesicular stomatitis virus G protein (VSV-G), and recent evidence
suggests that the ubiquitously expressed low-density lipid recep-
tor (LDL-R) plays a critical role in its viral entry (35). In this study,
we examined EC CD4 T cell resistance to different HIV enve-
lopes. We identified a subset of ECs in our cohort who exhibited
CD4 T cell resistance to R5-tropic HIV but full susceptibility to
X4-and VSV-G-enveloped viruses. We investigated transcrip-
tional signatures that were associated with cellular resistance and
determined that the MIP-1 and/or MIP-1 level was elevated in
three out of four individuals with the cellular resistance pheno-
type. These elevated levels of chemokines were necessary and suf-
ficient to confer this phenotype to other cells in a medium transfer
experiment.
MATERIALS AND METHODS
Peripheral blood mononuclear cell collection and CD4 T cell purifi-
cation. The Yale Human Investigations Committee and Texas Tech Uni-
versity Health Sciences Center Institutional Review Board approved all
studies involving human subjects. Following informed consent, blood was
collected from subjects by peripheral venous phlebotomy. Peripheral
blood mononuclear cells (PBMCs) were isolated by using Ficoll-Paque
Plus reagent (GE Healthcare Life Sciences, Piscataway, NJ), and CD4 T
cells were purified via magnetic enrichment using CD4 microbeads
(Miltenyi Biotech, San Diego, CA). Purity was judged to be between 85%
and 97% based upon flow cytometric analysis (the remaining cells were
predominantly CD4-low monocytes with 1% contaminating CD8 T
cells and 0.1% contaminating NK cells). Cells were frozen in 10% di-
methyl sulfoxide (DMSO)–90% fetal bovine serum (FBS) and stored un-
til use.
CD4T cell activation, single-cycleHIV infection assay, and condi-
tioned medium transfer. CD4 T cell aliquots were thawed and then
activated by using plates coated with 1 g/ml anti-CD3 (clone OKT3;
eBioscience, San Diego, CA) in the presence of 2g/ml soluble anti-CD28
(clone 28.2; eBioscience) and 100 IU/ml IL-2 for 3 days. They were then
infected with a replication-defective HIV vector encoding a fluorescent
reporter gene (enhanced yellow fluorescent protein [eYFP] or enhanced
green fluorescent protein [eGFP]) and individually pseudotyped with var-
ious R5, X4, and VSV-G envelopes, prepared as previously described (36).
Three days later, flow cytometry was performed with a FACSCalibur or
FACSCanto instrument (Becton Dickinson, Franklin Lakes, NJ) to quan-
tify green fluorescent protein-positive (GFP)/YFP HIV-infected cells.
For the R5-tropic viruses that exhibited a low level of infection, a large
number of cells (5	 104 to 2	 105) were analyzed, and gating was set on
mock-infected cells such that at most 1 out of 105 cells was scored positive.
Thus, with an infection rate of 1%, the dynamic range of the flow cyto-
metric assay was 1,000. In some experiments, cells were incubated in
supernatants harvested from CD4 T cells activated 3 days earlier or su-
pernatants from 293T cells transfected with the following plasmids:
pCCL3L1, encoding MIP-1 (Origene, Rockville, MD); pCCL4, encoding
MIP-1 (to generate this plasmid, the CCL4 coding sequence was ampli-
fied from human cDNA and then ligated into plasmid pcDNA3/1CAT);
and pK B-arr-HA, encoding -arrestin (a gift from Bryan Cullen, Duke
University). Treatment was performed in the absence or presence of 70
g/ml polyclonal goat IgG neutralizing antibodies against MIP-1 and/or
MIP-1 or the isotype control (R&D Systems, Minneapolis, MN), fol-
lowed by the addition of HIV-pseudotyped particles 20 min later.
QuantificationofT cell purification, activation, andCCR5 levels.To
assess CD4 T cell purity, activation status, and CCR5 levels, samples
were stained with fluorescently labeled antibodies against human
CD4-allophycocyanin (APC) (RPAT4), CD3-peridinin chlorophyll
protein (PerCP)-cyanine 5.5 (clone OKT3), CD8a-phycoerythrin (PE)
(HIT8a), and CD14-fluorescein isothiocyanate (FITC) (61D3) or
CCR5-PE (NP-6G4), CD69-FITC (FN50), CD25-PerCP (BC96),
CD337(NKp30)-PE (AF29-4D12), and CD56-FITC (TULY56) (all
from eBioscience). Cells were stained in 2% FBS in phosphate-buff-
ered saline (PBS) on ice for 30 min, washed in the same buffer, and
then fixed in intracellular (IC) fixation buffer (eBioscience) on ice for
10 min. Cells were washed and resuspended in 2% FBS in PBS, and
flow cytometry analysis was then performed with a FACSCalibur or
FACSCanto instrument (Becton Dickinson). Data were analyzed with
FlowJo software (Tree Star Inc., Ashland, OR).
RNA sequencing (RNA-Seq). Total RNA was isolated from CD4 T
cells of ECs and healthy donors by using the RNeasy minikit (Qiagen,
Germantown, MD). Isolated RNA was analyzed at the Yale Genome Anal-
ysis Center, where cDNA sequencing library preparation and Illumina
single-end sequencing were performed. DNA sequence data generated
were stored in FASTQ format, and quality control was performed by using
FastQC version 0.10.1 (37). Low-quality reads (Q  20) were removed
prior to alignment. Quality-filtered reads were aligned to sequences of the
human genome (hg19) downloaded from Illumina’s iGenome resource
(Illumina, San Diego, CA), using TopHat version 2.0.5 (38), as previously
described (39). Successfully aligned reads were then further analyzed by
using Cuffdiff in order to allow the estimation of differential gene expres-
sion using functions of the R package “cummeRbund” (40).
Whole-exome sequencing. Genomic DNA was isolated from 10 ml
whole blood by using the QIAamp DNA blood maxikit (Qiagen). Tar-
geted capture was performed by using the NimbleGen 2.1 exome reagent
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followed by sequencing on the Illumina Genome Analyzer IIx platform.
Sequences were aligned to NCBI build 36 of the human genome by using
the ELAND program (Illumina) for single nucleotide variation detection
and by BWA software for indel detection. Reads aligned out of the tar-
geted intervals and pairs of reads sharing the same start and end positions
were regarded as PCR duplicates and discarded. Single-nucleotide vari-
ants (SNVs) and indels were called from the remaining reads by using
Samtools software and annotated by using an in-house annotation pipe-
line. dbSNP (build 135) and 1000 Genomes (May 2011 release) were used
to test for novelty of variations.
qPCRand reverse transcription-PCR (RT-PCR).Genomic DNA and
total RNA were isolated as described above. cDNA was synthesized with
the Promega reverse transcription system using random primers (Pro-
mega, Madison, WI). The CCR5 genotype (
32 versus WT) was deter-
mined by quantitative PCR (qPCR) with primers CCR5-583F (5=-ACCT
CGAGCTCTCATTTTCC-3=) and CCR5-664R (5=-CCAGCCCCAAGAT
GACTATC-3=), as reported previously (41). To quantify CCR5, STAT-1,
C/EBP, and RUNX1 mRNA levels, relative to the EF1 reference gene,
qPCR was performed by using the iQ SYBR green Supermix reagent (Bio-
Rad), with primers CCR5-F1 (5=-CAAAAAGAAGGTCTTCATTACACC-
3=), CCR5-R1 (5=-CCTGTGCCTCTTCTTCTCATTTCG-3=), hSTAT1F
(5=-TGGGTTTGACAAGGTTCTT-3=), hSTAT-1R (5=-TATGCAGTGC
CACGGAAAG-3=) (42), CEBPaF (5=-CGGTGGACAAGAACAGCAAC-
3=), CEBPaR (5=-CGGAATCTCCTAGTCCTGGC-3=) (43), RUNX1F
(5=-ACTCGGCTGAGCTGAGAAATG-3=), RUNX1R (5=-GACTTGCGG
TGGGTTTGTG-3=), EF1aF (5=-TCTGGTTGGAATGGTGACAACAT
GC), and EF1aR (AGAGCTTCACTCAAAGCTTCATGG-3=) (44). To
measure the copy number of CCL3-like (CCL3L) and CCL4-like (CCL4L)
genes, qPCR was performed on genomic DNA by using the TaqMan no-
Amp Erase UNG reagent (Applied Biosystems, Life Technologies, Grand
Island, NY), with primers CCL3L1GF (5=-TCTCCACAGCTTCCTAACC
AAGA-3=), CCL3L1GR (5=-CTGGACCCACTCCTCACTGG-3=),
CCL4L1GF (5=-CCCTGGCCTTTCCTTTCAG-3=), CCL4L1GR (5=-AAG
CTTCCTCGCGGTGTAAG-3=), bglobinGF (5=-GGCAACCCTAAGGT
GAAGGC-3=), and bglobinGR (5=-GGTGAGCCAGGCCATCACTA-3=)
and the TaqMan probes CCL3L1P (5=– 6-carboxyfluorescein [FAM]–AG
GCCGGCAGGTCTGTGCTGA–6-carboxytetramethylrhodamine [TAMR
A]–3=), CCL4L1P (5=-FAM-CAGACCCTCCCACCGCCTGCT-TAMR
A-3=), and bglobinP (5=-VIC-CATGGCAAGAAAGTGCTCGGTGCCT-
TAMRA-3=) (Applied Biosystems) (45). A total of 6.6 ng DNA template
was used for this assay. A previous report indicated that the CEM cell line
contains 2 copies of both theCCL3L1 andCCL4L1 genes (46); this cell line
was used as a reference to determine the copy number for each EC
genomic DNA sample relative to the -globin gene. However, it has re-
cently emerged that there is a complex architecture within the locus en-
coding the CCL3-like and CCL4-like genes, including multiple full-length
and partial-length genes with a high degree of homology that may be
mutually amplified by these primers (47). Hence, results are reported as
the relative copy number (n) of CCL3-like and CCL4-like genes for each
individual, normalized to values for the CEM cell line (n 2), calculated
by using the means from three experimental replicates. Values obtained
are reported to at least two significant digits and not rounded to whole
integers.
HLA typing. The preliminary HLA-B type was determined via se-
quencing (Yale Department of Surgery Histocompatibility Laboratory
Service); B*57 alleles were subsequently resolved with the HLA B*57 SSP
genotyping kit (Olerup, Stockholm, Sweden).
ELISA. MIP-1, MIP-1, and RANTES instant enzyme-linked im-
munosorbent assay (ELISA) kits (eBioscience) were used to measure
chemokine levels in culture supernatants, according to the manufactur-
er’s instructions.
Graphs and statistics. Graphs show either representative results or
pooled results from at least two experimental repeats, as indicated in the
figure legends. For each assay, a normality test was performed on the
healthy control data, and a parametric or nonparametric test was then
performed as appropriate, followed by multiplicity-adjusted posttests for
selected pairs. The statistical tests used for each data set are reported in the
figure legends. The P values for pairwise tests, or multiplicity-adjusted
posttests of selected pairs, are reported on the graphs. For the transcrip-
tome analysis, P values were calculated by Cufflinks from the difference in
the distributions of observed log fold changes (i.e., Student’s t test on the
log2-fold change).
RESULTS
Recruitment of a cohort of HIV ECs. We identified 11 ECs from
local clinics in Southern Connecticut, using inclusion criteria of
HIV seropositivity, viral loads (VLs) of 400 copies/ml (before
2008) or48 or20 copies/ml (after 2008) on at least 2 occasions
separated by a minimum of 6 months in the absence of ART, and
no AIDS-defining illnesses. Exclusion criteria included clear viro-
logic failure (e.g., progressively increasing VLs) or any contrain-
dication to peripheral phlebotomy. Table 1 shows the clinical
characteristics of this cohort. The cohort was heterogeneous in
nature and included both genders and a mixture of races and
ethnicities. EC-1 met the study criteria at the time of enrollment
but subsequently had an elevated plasma viral load, accompa-
nied by a reduced CD4 T cell count, and began treatment with
efavirenz, emtricitabine, and tenofovir in 2013. EC-3 was pre-
scribed efavirenz, emtricitabine, and tenofovir in 2010 due to a
decreasing CD4 T cell count that occurred during chemother-
apy for rectal cancer, although his viral load remained unde-
tectable. The nine other patients remained ART naive. HLA
typing demonstrated that 7/11 patients in the cohort possess a
protective B*57 allele (EC-2, EC-4, EC-5, EC7, EC-8, EC-9, and
EC-11).
A subset of ECs exhibits a novel phenotype of CD4 T cell
resistance to R5-tropic single-cycle HIVs. In order to examine T
cell resistance to HIV infection in our cohort, we obtained blood
samples from recruited patients, purified CD4 T cells, and per-
formed a single-cycle HIV infection assay. A post hoc analysis re-
vealed a subset of four ECs (EC-1, -2, -3, and -11) whose CD4 T
cells exhibited relative resistance to YU2-pseudotyped virus, in
comparison to the remaining ECs (EC-4 through -10) and healthy
controls (Fig. 1A). In contrast, these T cells were fully susceptible
to VSV-G-pseudotyped particles (Fig. 1B). For EC-2 and EC-11,
we confirmed resistance by using a different HIV backbone and a
dose range of YU2 Env-pseudotyped virus (EC-1 and EC-3 were
excluded from this analysis because of limited sample availability)
(Fig. 1C). The T cells remained fully susceptible to VSV-G-pseu-
dotyped virus under similar conditions (Fig. 1D).
The contrasting results between YU2- and VSV-G-pseu-
dotyped virus led us to question whether the resistance phenotype
extended to other R5- and X4-tropic envelopes. We exposed
CD4 T cells to a panel of replication-defective viruses pseu-
dotyped with different envelopes. CD4T cells from EC-1, -2, and
-11 exhibited significant resistance to the YU2, JRFL, and ADA
R5-tropic envelopes, compared to normal controls (again, EC-3
was excluded from this analysis because of limited sample avail-
ability) (Fig. 1E). In contrast, these cells were fully susceptible to
viruses containing the HXB2-, NL4.3-, and LAI X4-tropic enve-
lopes as well as VSV-G (Fig. 1E).
Cellular resistance to R5-tropic HIV is not associated with
altered CCR5 levels. R5-tropic HIV envelopes mediate entry via
the CCR5 coreceptor, whereas X4-tropic HIVs utilize the CXCR4
coreceptor. To determine if altered CCR5 levels explained this
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phenotype, we harvested RNA from CD4 T cells after activation
and measured CCR5 levels by reverse transcription-quantitative
PCR (qRT-PCR). We observed similar CCR5 mRNA levels in all
subjects (Fig. 2A). Additionally, we quantified CCR5 surface pro-
tein levels on CD4 T cells by flow cytometry. We observed a
substantial upregulation of CCR5 upon activation of CD4 T
cells, and this occurred to a similar degree in all subjects (Fig. 2B).
Genotyping of CCR5, via qPCR, demonstrated that none of the
ECs in this cohort possessed the 
32 CCR5 mutation, which pre-
vents R5-tropic HIV entry (48). Additionally, whole-exome se-
quencing demonstrated that none of these subjects had mutations
in their CCR5 or CD4 exonic sequences. Hence, altered CCR5
coding sequences or levels of expression did not account for resis-
tance to R5-tropic virus. Upon CD4 T cell activation, CD25 was
upregulated to a similar degree in all of the ECs and healthy con-
trols, suggesting a comparable activation status (Fig. 2C). How-
FIG 1 A subset of ECs shows CD4 T cell resistance to R5-tropic HIV. (A and B) CD4 T cells from the ECs and healthy controls were activated for 3 days with
anti-CD3 and anti-CD28.2 in the presence of IL-2. Cells were then infected with replication-defective HIV-cycT1-internal ribosome entry site (IRES)-eYFP
pseudotyped with YU2 (R5 tropic) (A) or VSV-G (pantropic) (B). (C and D) A dose response analysis was performed with replication-defective HIV-ec2GFP
pseudotyped with the YU-2 envelope (C) or VSV-G (D). Panels A to D show results of one representative experiment with 3 healthy controls. Data were analyzed
by using the Kruskal-Wallis test and Dunn’s multiple-comparison test. (E) Replication-defective HIV-cycT1-IRES-eYFP or HIV-ec2GFP pseudotyped with a
panel of envelopes, including VSV-G, YU2, JRFL, and ADA (R5) and HXB2, NL4.3, and Lai (X4). Shown are pooled results from three experimental repeats with
11 healthy control samples for the ADA envelope and 7 healthy control samples for the other envelopes. Data were analyzed separately for each envelope with the
Mann-Whitney test. Graphs show individual values and medians. n.s., not significant.
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ever, CD69 upregulation was slightly reduced in resistant ECs 1, 2,
3, and 11 (Fig. 2D).
Transcriptional signatures associated with the cellular R5-
tropic HIV resistance phenotype. We investigated whether spe-
cific transcriptional signatures were associated with the CD4 T
cell resistance phenotype. We activated CD4 T cells from two of
the resistant ECs (EC-2 and EC-11) and three healthy controls,
prepared RNA, and performed exploratory RNA-Seq transcrip-
tome analyses (EC-1 and EC-3 were again excluded from this
analysis because of limited sample availability). The levels of 17
genes were statistically significantly different between the resistant
ECs and healthy controls (Table 2). Of the genes on this list, we
were intrigued by the presence of CCL3 and CCL3L1, both of
which encode MIP-1. MIP-1, MIP-1, and RANTES are natu-
ral ligands of CCR5 that inhibit R5-tropic HIV infection by steric
hindrance of virus binding (49–52). The CCL3 and CCL3L1 genes
were both upregulated in EC-11 versus healthy controls. In con-
trast, EC-2 had only slightly elevated levels of CCL3 and levels of
CCL3L1 similar to those in healthy controls (Table 2).
Cellular resistance to R5-tropic HIV is associated with in-
creased levels ofMIP-1 and/orMIP-1 in EC-1, -3, and -11.To
determine whether the secreted amounts of MIP-1 and the re-
lated chemokines MIP-1 and RANTES were elevated, we har-
vested supernatants from activated CD4 T cells immediately
FIG 2 CCR5 mRNA levels and CCR5 and CD25 protein levels are not altered in CD4 T cells from resistant ECs, while CD69 levels are reduced in resistant ECs.
(A) mRNA levels of CCR5 in activated CD4 T cells relative to the EF1a control (results from one representative experimental repeat with 3 healthy controls).
(B to D) Cell surface levels of CCR5 (B), CD25 (C), and CD69 (D), as measured by flow cytometry, in freshly thawed and activated CD4 T cells (results from
two pooled experiments with 9 healthy controls). Data were analyzed with the Kruskal-Wallis test and Dunn’s multiple-comparison test. Graphs show individual
values and medians.
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prior to the infection assay and measured chemokine levels via an
ELISA. T cells from EC-3 and EC-11 exhibited a significant in-
crease in MIP-1 production relative to healthy controls (Fig.
3A), whereas levels for EC-1 and EC-2 were similar to those for
healthy controls. The level of MIP-1 production was elevated in
EC-1, EC-3, and EC-11 relative to healthy controls (Fig. 3B),
whereas EC-2 levels were similar to those in healthy controls.
RANTES production did not show a significant differences be-
tween the samples (Fig. 3C). Additionally, we measured MIP-1
levels in serum isolated from these patients. In contrast to the
results obtained for activated CD4 T cell media, MIP-1 levels
were similar in the sera of both resistant ECs and healthy controls
(Fig. 3D).
CCL3-like and CCL4-like gene copy numbers are elevated in
EC-1, EC-2, andEC-3, and theSTAT-1mRNAexpression level is
elevated in EC-11. The CCL genes encoding MIP-1, MIP-1,
and RANTES lie in a cluster at chromosome 17q12 (53). The orig-
inal genes, CCL3 and CCL4, are each present as a single copy and
encode MIP-1 and MIP-1, respectively. However, segmental
duplication of this region has resulted in additional genes that
exhibit copy number variation (CNV) (47). This CNV locus in-
cludes the full-length CCL3-like (CCL3L) genes CCL3L1 and
CCL3L3 as well as a truncated gene, CCL3L2. These genes exhibit
a high degree of homology to each other and the CCL3, with
CCL3L1 being identical to CCL3L3 at the nucleotide level. Like-
wise, there are multiple CCL4-like (CCL4L) genes in this region,
including CCL4L1 and CCL4L2, which are identical to each other
at the amino acid level and highly homologous to CCL4. More-
over, this CNV region exhibits a complex architecture, with vari-
ations in breakpoints and CNVs inserted into larger CNVs (47).
The relative CCL3L gene copy number varies among different
ethnic and racial backgrounds. The CCL-like gene copy number
regulates chemokine production levels (45, 46). Some studies sug-
gest that individuals with a high gene copy number (n) in relation
to their racial background are less likely to seroconvert and have a
lower rate of HIV progression to AIDS if seropositive (46).
CCL3-like and CCL4-like gene copy numbers were therefore
quantified by qPCR. Both EC-1 and EC-3 exhibited high relative
copy numbers ofCCL3-like genes (n 17.0 and 11.8, respectively)
(Fig. 4A) and CCL4-like genes (n  8.4 and 8.1, respectively)
(Fig. 4B) for individuals of European descent. It is therefore likely
that the higher relative copy numbers of CCL3-like genes and
CCL4-like genes explain the increased levels of production of
MIP-1 in EC-3 and MIP-1 in both individuals. Additionally,
EC-2 exhibited a somewhat elevated relative gene copy number
for an individual of African descent (CCL3-like genes, n  13.3
[Fig. 4A]; CCL4-like genes, n  6.1 [Fig. 4B]), although we de-
tected a normal level of chemokine production by ELISA and
transcriptome analyses (Fig. 3 and Table 2). In contrast, EC-11
exhibited an intermediate relative gene copy number for an indi-
vidual of African ancestry (CCL3-like genes, n  6.7 [Fig. 4A];
CCL4-like genes, n 3.2 [Fig. 4B]). It is therefore unlikely that the
gene copy number is responsible for the increased levels of chemo-
kines in EC-11. Whole-exome sequencing demonstrated that
none of the patients in our cohort had mutations inCCL3 orCCL4
exonic sequences.
In order to further explore the mechanism of the increase in
MIP levels in EC-11, we utilized qPCR to quantify the levels of
three transcription factors that bind to the promoters of theCCL3,
CCL3-like, CCL4, and CCL4-like genes. STAT-1 mRNA levels
were elevated in EC-11 T cells versus healthy control T cells (Fig.
4C). In contrast, RUNX1 and C/EBP mRNA levels were similar
between EC-11 and control T cells (data not shown).
MIP-1 and MIP-1 produced by EC-3 and EC-11 CD4 T
cells are necessary and sufficient to confer the R5-tropic HIV
cellular resistance phenotype in amedium transfer experiment.
We employed a medium transfer experiment to determine
whether the high levels of MIP-1 and MIP-1 were responsible
TABLE 2 Transcriptome analysis of activated CD4 T cells from EC-2 and EC-11 versus healthy controlsa
Gene
Transcriptome expression value (no. of fragments/kb of exon/million fragments mapped)
Fold change P valueEC-2 EC-11 HC-1 HC-2 HC-3 EC mean HC mean
IFIT2 1.94 21.55 0.68 1.75 3.35 11.78 1.93 6.09 2.17E06
IFIT3 3.17 31.30 1.49 1.92 6.42 17.24 3.29 5.24 1.23E05
LYZ 21.51 21.49 7.77 3.16 5.01 22.18 5.49 4.04 6.73E05
IFNG 495.03 222.40 180.08 86.80 54.94 357.77 107.56 3.33 1.03E06
CCL3 93.34 296.99 60.19 47.49 65.60 196.01 58.45 3.35 8.93E06
CCL3L1 1.52 38.95 1.02 0.35 3.33 20.26 1.59 12.75 2.79E06
IL1B 37.06 50.56 10.20 6.02 9.63 43.98 8.63 5.10 1.17E07
CLDN1 0.70 0.52 1.41 10.52 0.30 0.60 4.05 0.15 6.87E05
IL-8 46.05 126.72 22.54 10.24 22.57 83.91 17.27 4.86 7.74E09
CXCL5 0.22 9.00 0.80 0.35 0.63 4.60 0.57 8.01 3.06E05
IL-2 0.69 9.10 0.12 0.41 0.18 4.89 0.24 20.79 3.15E05
IL-9 178.61 60.90 22.08 9.42 3.15 131.12 12.31 10.65 4.15E10
LTA 231.21 324.48 62.05 105.74 76.26 272.36 80.08 3.40 1.78E07
TNF 19.55 27.70 5.15 5.20 8.23 22.72 5.99 3.79 5.58E05
IL17A 5.50 49.91 3.23 3.80 6.26 27.58 4.39 6.29 4.15E07
IL17F 243.39 777.42 133.68 74.58 44.55 513.38 86.05 5.97 9.06E12
IDO1 19.03 31.55 10.72 3.24 4.41 25.27 6.18 4.09 1.27E05
a Transcriptome expression values (fragments per kilobase of exon per million fragments mapped) for EC-2, EC-11, and three healthy controls (HCs) (HC-1, HC-2, and HC-3) are
shown. For the 17 genes shown, expression values were significantly different between ECs and healthy controls. Please note that this table omits a duplicate entry for CCL3L1; two
processed pseudogenes, PSPHP1 and RP11-10B2.1.1; and two transcripts with no database entry, which were also significant. P values were calculated from the difference in the
distribution of observed log fold changes (i.e., Student’s t test on the log2 fold change) by using Cufflinks.
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for the observed T cell-intrinsic resistance of EC-3 and EC-11. We
treated activated CD4 T cells from a healthy donor with cell
culture supernatants from EC-3, EC-11, or healthy control CD4
T cells and then infected these cells with YU2-pseudotyped HIV.
EC-3 and EC-11 supernatants suppressed YU2-pseudotyped HIV
infection relative to healthy control supernatants (Fig. 5A). Fur-
thermore, the addition of anti-MIP-1 and anti-MIP-1 neutral-
izing antibodies reversed this effect (Fig. 5A). These data suggest
that a secreted factor(s) from EC-3 and EC-11 T cells confers
cellular resistance to R5-tropic HIV and that MIP-1 and MIP-1
are necessary for this effect. In contrast, supernatants from EC-3
and EC-11 T cells did not alter infection by HXB2-pseudotyped
HIV (Fig. 5B).
In a separate experiment, we treated CD4T cells from healthy
controls with culture supernatants from cells transfected with
pCCL3L1 (encoding MIP-1), pCCL4 (encoding MIP-1), a
control plasmid encoding -arrestin, or complete RPMI. These
cells were then infected with YU2-pseudotyped virus. Superna-
tants containing MIP-1 or MIP-1 suppressed YU2-pseu-
dotyped HIV infection relative to that of the -arrestin control
(Fig. 5C). The addition of the appropriate neutralizing antibody
reversed this effect (Fig. 5C). These data indicate that MIP1- and
MIP-1 are indeed sufficient to inhibit R5-tropic HIV infection.
DISCUSSION
This study demonstrates a novel HIV cellular resistance pheno-
type in a subset of ECs: CD4 T cells were intrinsically resistant to
R5-tropic HIV but fully susceptible to X4-tropic and VSV-G-
pseudotyped HIV for 4 of 11 patients in our cohort (EC-1, -2, -3,
and -11). The remaining patients in the cohort likely accomplish
HIV control via other mechanisms that may be CD4 T cell ex-
trinsic. These and previous studies support the notion that ECs are
a diverse group of patients who accomplish HIV control via mul-
tiple distinct and unknown mechanisms.
Previous studies investigated whether ECs harbor CD4T cells
that are intrinsically resistant to HIV infection but obtained mixed
results (24–34). We speculate that these conflicting results are a
consequence of the different experimental conditions among
these studies. Viral infection rates may be influenced by the CD4
T cell activation protocol, the physiological state of the cells, the
viral strains used, viral titers, cell density, the frequency of me-
dium change, and the use of spinoculation or lack thereof. It is
possible that the specific experimental conditions used in our
study are critical to observe the phenotype of R5-tropic resistance
in a subset of ECs. Alternatively, the patient characteristics of our
cohort may be unique. Although it would be of interest to deter-
FIG 3 Increased production of CCR5 ligands by EC-3 and EC-11 CD4 T cells. (A to C) CD4 T cells from EC-2, EC-3, EC-11, and healthy controls were
activated for 3 days, and levels of chemokines in the culture supernatant, including MIP-1 (A), MIP-1 (B), and RANTES (C), were measured by an ELISA.
Pooled results from three experimental repeats with 11 healthy control samples are shown. (D) Serum was obtained from EC-1, EC-2, EC-3, EC-11, and healthy
controls, and the MIP-1 level was measured by an ELISA. Pooled results from two experimental repeats with 9 healthy control samples are shown. Data were
analyzed by one-way analysis of variance and Bonferroni’s multiple-comparison test. Graphs show mean values and standard errors of the means.
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mine HIV tropism in these ECs, the low levels of plasma viremia
make it extremely challenging to do so.
For three patients in our cohort, EC-1, EC-3, and EC-11, we
determined that increased levels of MIP-1 and/or MIP-1 secre-
tion were associated with cellular resistance. Activated CD4 T
cells from these patients produced significantly more MIP-1
(EC-3 and EC-11) and more MIP-1 (EC-1, EC-3, and EC-11)
than did those from healthy controls. The level of RANTES pro-
duction was not elevated in these patients. We did not observe an
elevation in chemokine levels in the sera of these patients. It is
likely that CD4 T cells must be activated to induce chemokine
production. Alternatively, it is possible that even unactivated
CD4T cells produce more chemokines in these patients, but this
is not sufficient to elevate serum levels. Even in the absence of
elevated serum chemokine levels, MIP-1 locally produced by
activated CD4 T cells could bind cell surface CCR5 in an auto-
crine or paracrine fashion, inhibiting the entry of R5-tropic HIV.
High relative copy numbers of CCL3-like and CCL4-like genes
were detected in EC-1 and EC-3 and likely account for the in-
creased chemokine production that we observed in CD4 T cells
from these patients. Interestingly, the relative copy numbers of
CCL3-like and CCL4-like genes were also somewhat elevated in
EC-2. However, this individual displayed normal CCL3L1 gene
expression levels and normal MIP-1/ levels in stimulated T cell
culture supernatants. It remains plausible that an elevated CCL
copy number is somehow mechanistically responsible for cellular
resistance in EC-2 despite not exhibiting an obvious elevation at
the RNA or protein level in CD4 T cells. In contrast, EC-11 had
intermediate relative copy numbers of CCL3-like and CCL4-like
genes for an individual of African ancestry. Hence, the copy num-
ber does not explain the elevated levels of chemokine production
that we observed for this individual. EC-11 exhibited elevated
mRNA levels of STAT-1, a transcription factor with a binding site
in the CCL gene promoters. Elevated STAT-1 levels may thus play
a role in cellular resistance in EC-11. However, the mechanism for
the elevation of STAT-1mRNA levels in this individual remains to
be fully explored.
In a medium transfer experiment, secreted products from
EC-3 and EC-11 CD4 T cells were sufficient to confer cellular
resistance to R5-tropic HIV. MIP-1 and MIP-1 were necessary
for this effect, since chemokine-neutralizing antibodies fully re-
versed the phenotype. Additionally, transfected medium contain-
ing the MIP-1 or MIP-1 chemokine suppressed R5-tropic HIV
infection, indicating that the chemokines themselves were also
sufficient for these effects, consistent with data from previous re-
ports (30, 54).
Previous studies obtained mixed results regarding the associa-
tion between the CCL3L1 and CCL4L1 copy numbers and HIV/
FIG 4 High relative copy numbers of CCL3-like and CCL4-like genes in EC-1, EC-2, and EC-3 and elevated STAT-1 mRNA levels in EC-11. (A and B) Relative
copy numbers ofCCL3-like (A) andCCL4-like (B) genes in ECs relative to the CEM cell line (n 2). The dashed line indicates the average CCL3L1 copy number
for individuals of African and European descent. The bar pattern indicates the ethnicity of each individual. Graphs show pooled results from two qPCR assays,
each run in duplicate. Data were analyzed by one-way analysis of variance and Bonferroni’s multiple-comparison test. (C) STAT-1 mRNA levels in EC-11 versus
healthy controls relative to the EF1a mRNA control. Graphs show pooled results from two experimental repeats with 8 healthy control samples. Data were
analyzed with a t test. Graphs show mean values and standard errors of the means.
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AIDS susceptibility and disease progression (reviewed by Hollox
and Hoh [55]). For example, some reports demonstrated an asso-
ciation between high CCL3L1 copy numbers and a reduced prev-
alence of HIV seropositivity, slower progression to AIDS, and im-
proved recovery of CD4 T cells (45, 56–58), whereas other
studies and follow-up correspondences failed to detect an associ-
ation even within the same data set (59–61). Some researchers
have suggested that the CCL3L1 copy number estimation method
used in those association studies could be flawed, for example, due
to DNA degradation, inconsistent quality among DNA samples,
the use of inappropriate DNA amounts in the real-time PCR as-
say, inappropriate comparison of threshold cycle (CT) values from
samples run in different real-time PCR experimental repeats, or
inappropriate rounding of copy numbers to the nearest integer
value. Of note, every DNA sample used in our study was isolated
by the same investigator, using the same purification method. The
DNA obtained was found to be of high quality, with a 260/280-nm
light absorbance ratio of 1.8 and no obvious degradation, as
evidenced by agarose gel electrophoresis of the samples. The
amount of DNA used for the real-time PCR assay was 6.6 ng for
every sample, and all samples were included in every experimental
replicate, with consistent values being observed between repli-
cates. A serial dilution of the CCL3L1 plasmid DNA and genomic
DNA suggested that the CT of the samples was within the range in
which the 2

CT method yielded an appropriate estimation of the
gene copy number. We did not round our copy number values to
an integer but instead reported them to two or three significant
digits. Finally, previous reports criticized the fact that multiple
reports that found a positive association used duplicated patient
cohorts. In contrast, the patient cohort in this report is unique and
was not used in any previous studies.
Protective HLA alleles were previously implicated as a deter-
mining factor in HIV control versus progression (10). Most nota-
bly, the B*57 alleles are associated with HIV control. Seven of 11
FIG 5 MIP-1 and MIP-1 are necessary and sufficient to confer R5-tropic HIV resistance in a medium transfer experiment. (A and B) CD4 T cells from healthy
donors were treated with the activated CD4 T cell culture supernatant from EC-3 or EC-11 in the presence or absence of anti-MIP-1 and -MIP-1 neutralizing
antibodies or with the activated CD4T cell culture supernatant from a healthy control prior to the addition of HIV particles pseudotyped with YU2 (A) or HXB2 (B).
(C) CD4 T cells from healthy controls treated with the cell culture supernatant from 293T cells transfected with either pCCL3L1, encoding MIP-1, or pCCL4,
encoding MIP-1, in the presence or absence of the appropriate neutralizing antibodies; medium from cells transfected with a-arrestin-encoding plasmid; or complete
RPMI, prior to the addition of YU2-pseudotyped HIV particles. Graphs show results from one representative experimental repeat, run in duplicate. Data were analyzed
by one-way analysis of variance and Bonferroni’s multiple-comparison test. Graphs show mean values and standard errors of the means.
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patients in our cohort possessed B*57 alleles (EC-2, EC-4, EC-5,
EC7, EC-8, EC-9, and EC-11), including two of the elite control-
lers who exhibited the pattern of R5-tropic cellular resistance de-
scribed in this report (EC-2 and EC-11). It is plausible that CD4
T cell resistance synergizes with an HLA-based mechanism (i.e.,
enhanced CD8 T cell response to HIV antigens) to control HIV
replication in these patients. We also observed reduced CD69 up-
regulation upon CD4T cell activation in the resistant ECs versus
healthy controls. The significance of this finding is unclear.
In summary, the factors contributing to the natural control of
HIV are likely multifactorial. Increased production of MIP-1
and MIP-1 can now be added as a mechanism that drives cellular
resistance to R5-tropic virus in some of these individuals, likely
contributing to their EC phenotype. Future studies will be re-
quired to determine precisely how the levels of these chemokines
are elevated in EC T cells and their relative importance among all
ECs and LTNPs. While limited by a small sample size, our findings
support the continued investigation of coreceptors as a target for
drug development and functional eradication of HIV. Whether
the expression levels of the natural ligands for CCR5 or CXCR4
can be increased for therapeutic benefit with minimal risk remains
to be explored.
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